The 21st Century Cures Act, passed in 2017, required that OHRP and FDA harmonize their regulations so that all human subject research is effectively being conducted under the same rules. While the new Common Rule, effective on January 21, 2019, does not apply to FDA-regulated research, FDA has already made clear their intent to update their own regulations to become consistent with these changes. This document summarizes the regulatory changes that apply to informed consent documents to provide extra-regulatory and informal guidance where helpful, to help sponsors update informed consent document templates to be compliant with the new regulations.
Other content in this Stream
In 2018 WIRB approved 100% of the single-patient EA requests that were submitted for review.
The impact of participant payments on clinical trial recruitment.
For biopharma sponsors, investigators, patients and families, these limitations are already translating into real impacts on development programs.
Studies show clinical trial participants want to know what was learned from their involvement. Many sponsors are implementing plans to deliver plain language summaries to trial participants.
Small and emerging biopharmas are conducting almost 50% of clinical trials in the U.S., often with lean teams, resources and infrastructure. Learn how to reduce the pressure on teams and timelines.
In June of 1966, physician-researcher Henry K. Beecher published a paper entitled “Ethics and Clinical Research.” Explore the history and motivation that led to Dr. Beecher’s ground-breaking paper.
Learn status of the requirements and recommendations for data-sharing from EMEA, FDA and PhRMA, and how to determine the steps to navigate the complicated field of data transparency compliance.
Learn about the regulatory framework that governs the use of investigational drugs outside clinical trials (formerly called “compassionate use”), and the ethical challenges surrounding it.